SHR-A1904 Compared With Investigator's Choice of Therapy in Claudin18.2 Positive Patitens With Second-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma

NCT06649292 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

524

Enrollment

INDUSTRY

Sponsor class

Conditions

Second-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma

Interventions

DRUG: SHR-A1904
DRUG: Paclitaxel, Docetaxel, Irinotecan

Sponsor

Shanghai Hengrui Pharmaceutical Co., Ltd.